Document is current
Any future updates will be listed below
-
Authors
Carapito, Raphael
Aouadi, Ismail
Verniquet, Martin
Untrau, Meiggie
Pichot, Angélique
Beaudrey, Thomas
Bassand, Xavier
Meyer, Sébastien
Faucher, Loic
Posson, Juliane
Morlon, Aurore
Kotova, Irina
Delbos, Florent
Walencik, Alexandre
Aarnink, Alice
Kennel, Anne https://orcid.org/0000-0002-3876-7456
Suberbielle, Caroline
Taupin, Jean-Luc
Matern, Benedict M. https://orcid.org/0000-0002-9548-732X
Spierings, Eric https://orcid.org/0000-0001-9441-1019
Congy-Jolivet, Nicolas
Essaydi, Arnaud
Perrin, Peggy
Blancher, Antoine
Charron, Dominique
Cereb, Nezih
Maumy-Bertrand, Myriam
Bertrand, Frédéric
Garrigue, Valérie
Pernin, Vincent
Weekers, Laurent https://orcid.org/0000-0002-3151-4640
Naesens, Maarten https://orcid.org/0000-0002-5625-0792
Kamar, Nassim
Legendre, Christophe
Glotz, Denis
Caillard, Sophie
Ladrière, Marc
Giral, Magali
Anglicheau, Dany
Süsal, Caner
Bahram, Seiamak https://orcid.org/0000-0002-6928-9952
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-11-LABX-0070_TRANSPLANTEX, ANR-10-IDEX-0002, ANR-20-SFRI-0012)
Institut National de la Santé et de la Recherche Médicale (U1109)
Institut Universitaire de France (Senior Member)
- License Information
-
More Information
Article History
Received: 14 June 2021
Accepted: 31 January 2022
First Online: 14 March 2022
Competing interests
: D.A. has a patent ‘In vitro method for determining the likelihood of occurrence of an acute microvascular rejection (AMVR) against a renal allograft in an individual’ (EP19305037.4) issued. S.B. reports grants and personal fees from BIOMICA and personal fees from GenDx. S.C. reports non-financial support from Sanofi and Astellas, and non-financial support from Novartis, outside the submitted work. N.K. reports personal fees from Abbvie, Amgen, Astellas, Biotest, CSL Behring, Chiesi, Gilead, Fresenius Medical care, Merck Sharp and Dohme, Neovii, Novartis Pharma, Sanofi, Sandoz and Shire, outside the submitted work. P.P. reports personal fees from Chiesi, outside the submitted work. All other authors have no competing interests.
